Jane S. Ricciuti, RPh, MS

Disclosures

December 27, 2002

In This Article

Introduction

Forteo (teriparatide [rDNA origin]) injection is a new drug that was approved in November 2002 by the US Food and Drug Administration (FDA). Forteo is a recombinant human parathyroid hormone product indicated for the treatment of osteoporosis. In addition to this agent, the FDA recently approved Alinia (nitazoxanide), Abilify (aripiprazole), and Strattera (atomoxetine).

Alinia is used for the treatment of diarrhea caused by Cryptosporidium parvum and Giardia lamblia in pediatric patients. Abilify is a new psychotropic agent approved for the treatment of schizophrenia. Strattera is a selective norepinehprine reuptake inhibitor indicated for the treatment of attention deficit/hyperactivity disorder (ADHD).

This month's column reviews FDA new product approvals and labeling changes for:

Antibiotic agents

  • Alinia (nitazoxanide)

Antidepressants

  • Zoloft (sertraline hydrochloride)

Attention deficit/hyperactivity disorder agents

  • Strattera (atomoxetine)

Cardiovascular agents

  • Lipitor (atorvastatin)

Dermatologic agents

  • Accutane (isotretinoin)

Diagnostic hormones

  • SecreFlo (secretin)

Gastrointestinal agents

  • Aciphex (rabeprazole)

Nonsteroidal anti-inflammatory agents

  • Bextra (valdecoxib) tablets

Osteoporosis agents

  • Forteo (teriparatide [rDNA origin]) injection

Psychotropic agents

  • Abilify (aripiprazole)

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....